Pro 2013-021 (Jianfeng Group Corporate Bond Listing Announcement)-1
Release time:
2020-08-05
Stock Abbreviations: Jianfeng Group Stock Code: 600 668 Announcement No.: Pro 2013- 021
Bond Abbreviations: 13 Peak 01 Bond Code: 122227

Zhejiang Jianfeng Group Co., Ltd.
201 3 Corporate Bonds (Phase I)
Listing Announcement
Securities Abbreviation: 13 Peak 01
Securities Code: 122227
Total Issue: RMB 3 billion Yuan
Listing Time: 2013 7 2
Listing place: shanghai Stock Exchange
Sponsor (Lead Underwriter) / Listing Recommender
( Registered Address: hangzhou Hangzhou Hangzhou Hangzhou Road 1 )
2013 7 January
Section I Introduction
Important Tips
Zhejiang Jianfeng Group Co., Ltd. (the following is called "Jianfeng Group ", "Company" or "Issuer") Members of the Board of Directors have approved this Listing Announcement, guarantee that there are no false records, misleading Chen or material omissions, and assume individual and joint legal responsibility for its truthfulness, accuracy and completeness.
The approval of the Shanghai Stock Exchange (hereinafter referred to as the "SSE" ) for the listing of corporate bonds does not indicate a substantive judgment or guarantee of the investment value of the bonds or the return of investors. Investors who purchase bonds are responsible for the investment risks arising from changes in the company's operations and earnings. 117.
has been comprehensively evaluated byof United Credit Rating Co., Ltd. (hereinafter referred to as "United Rating " ). Jianfeng Group current corporate bonds Credit rating is AA + , and the main credit rating is AA ; Before the listing of bonds, the net assets of the issuer at the end of the latest period were ,164,643.81 .38 million yuan (total owner's equity of in the consolidated statement as of 2012 , 142# December , March 31 ) , and the asset-liability ratio of consolidated statement caliber was 40.74 (the asset-liability ratio of parent company caliber was 25.77 ); before the listing of the current bonds, the average annual distributable profit realized by the issuer in the last three fiscal years was 18,836.85 .56 million yuan (average of the net profit attributable to the owners of the parent company in the consolidated statements of 20 10 , 2011 and 201 2 #), expected not less than 1.5 times the one-year interest on this issue bonds. Section II Issuer Profile
1. Issuer Legal Name
Chinese Name: Zhejiang Jianfeng Group Co., Ltd.
English Name: ZHEJIANG JIANFENG GROUP CO.,LTD
2. Issuer Registered Address and Office Address
Registered Address: No. 88 193, Wujiang East Road, Jinhua City, Zhejiang Province
Office Address: No. 88 199, Wujiang East Road, Jinhua City, Zhejiang Province
3. Issuer Registered CapitalRegistered Capital: RMB 344,083,828.00 RMB
4. Issuer Legal Representative
Legal Representative: Jiang Xiaomeng
5. Issuer Basic Information
(I) Issuer Business Scope
Issuer's business scope is:cement, cement concrete, prefabricated components, common machinery, auxiliary materials, communication equipment, caulking materials, instruments and meters, paper bags manufacturing and sales, import and export business (see approval of the Foreign Trade Office for details), and industrial investment.
Main Business of (II) Issuers
According to "Guidelines for Industry Classification of Listed Companies (2012
Revision)" (CSRC Announcement [2012 ]
31), issuers belong to "Non-metallic Mineral Products Industry" and "Pharmaceutical Manufacturing Industry". The issuer's main business is cement manufacturing and sales, pharmaceutical manufacturing and sales, pharmaceutical commercial circulation. cement business is carried out in daye peak and Yunnan peak system, the issuer's holding subsidiaries. the issuer has been engaged in this business since was listed in 1993 , accounting for about 40% of the issuer's main business income. this business is mainly engaged in the production and sales of cement and cement clinker.
pharmaceutical business is carried out within the peak pharmaceutical system of the issuer's holding subsidiary, accounting for about 50% of the issuer's main business income . The business mainly covers two categories: pharmaceutical industry and pharmaceutical commerce. Company
2010, 2011 and 2012
, with operating income of132, .09 .63 million yuan, 164, .88 .65 million yuan and 164,909.55 .67 million yuan respectively, operating income stable growth ; the proportion of main business income to operating income is above 99% . The composition of the company's main business income in the past three years is as follows: units: ten thousand yuan
industry name
2012 degree |
2011 year |
2010 year |
amount |
|||
Proportion |
Amount |
Proportion |
Amount |
Proportion |
Cement Industry |
|
63,012.93 |
38.38% |
72,736.61 |
44.45% |
51,038.47 |
38.83% |
Pharmaceutical Industry |
82,785.43 |
50.42% |
76,543.88 |
46.77% |
65,262.72 |
49.66% |
other industries |
18,379.87 |
11.20% |
14,366.78 |
8.78% |
|||
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11